ALEC Logo

Alector, Inc. (ALEC) 

NASDAQ
Market Cap
$226.71M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
528 of 966
Rank in Industry
285 of 554

Largest Insider Buys in Sector

ALEC Stock Price History Chart

ALEC Stock Performance

About Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Insider Activity of Alector, Inc.

Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $1.4M worth of Alector, Inc. stock.

On average, over the past 5 years, insiders at Alector, Inc. have bought $1M and sold $56.03M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.

List of Insider Buy and Sell Transactions, Alector, Inc.

2024-12-02SaleChief Executive Officer
52,172
0.0534%
$2.52$131,442-12.55%
2024-12-02SalePresident and Head of R&D
26,500
0.0271%
$2.52$66,764-12.55%
2024-12-02SaleChief Medical Officer
14,892
0.0152%
$2.52$37,519-12.55%
2024-12-02SaleChief Financial Officer
16,489
0.0169%
$2.52$41,542-12.55%
2024-09-03SaleChief Executive Officer
26,499
0.0282%
$4.88$129,387+4.03%
2024-09-03SalePresident and Head of R&D
13,926
0.0148%
$4.88$67,981+4.03%
2024-09-03SaleChief Medical Officer
8,478
0.009%
$4.88$41,385+4.03%
2024-09-03SaleChief Financial Officer
7,297
0.0078%
$4.88$35,620+4.03%
2024-08-22Saledirector
44,250
0.0463%
$5.16$228,388-2.56%
2024-08-12Saledirector
5,000
0.0051%
$5.06$25,309-1.76%
2024-08-12Saledirector
10,500
0.0108%
$5.06$53,179-1.76%
2024-06-03SaleChief Executive Officer
25,135
0.0249%
$4.80$120,618-1.38%
2024-06-03SalePresident and Head of R&D
13,206
0.0131%
$4.80$63,373-1.38%
2024-06-03SaleChief Medical Officer
8,040
0.008%
$4.80$38,582-1.38%
2024-06-03SaleChief Financial Officer
6,920
0.0068%
$4.80$33,208-1.38%
2024-03-04SaleChief Executive Officer
18,837
0.0195%
$6.92$130,386-24.93%
2024-03-04SalePresident and Head of R&D
10,169
0.0105%
$6.92$70,387-24.93%
2024-03-04SaleChief Medical Officer
6,001
0.0062%
$6.92$41,554-24.93%
2024-03-04SaleChief Financial Officer
5,716
0.0059%
$6.92$39,562-24.93%
2023-12-04SaleChief Executive Officer
23,831
0.028%
$5.56$132,500-0.71%

Insider Historical Profitability

<0.0001%
Rosenthal ArnonChief Executive Officer
2507074
2.56%
$2.32019
Kenkare-Mitra SaraPresident and Head of R&D
565215
0.5771%
$2.3208
Romano GaryChief Medical Officer
349283
0.3567%
$2.32010
GRASSO MARCChief Financial Officer
330651
0.3376%
$2.3208
Yaffe Kristinedirector
67709
0.0691%
$2.3201
Hammond Pauladirector
60209
0.0615%
$2.3201
SCHELLER RICHARD Hdirector
35000
0.0357%
$2.3204
MCGUIRE TERRANCE
10853817
11.0829%
$2.3202
Polaris Venture Management Co. VI, L.L.C.10 percent owner
10853817
11.0829%
$2.3202
GORDON CARL L
10434976
10.6553%
$2.3210+10.01%
ORBIMED ADVISORS LLC10 percent owner
1906718
1.947%
$2.32117+10.01%
Oney SabahChief Business Officer
573918
0.586%
$2.32011
King RobertChief Development Officer
529295
0.5405%
$2.32011
Paul RobertChief Medical Officer
234319
0.2393%
$2.32037
SULIMAN SHEHNAAZPresident and COO
102598
0.1048%
$2.3204
Yu CalvinVice President, Finance
76686
0.0783%
$2.3208
Wehner David M.director
44621
0.0456%
$2.3210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$86.46M14.914.36M+13.8%+$10.49M0.01
BlackRock$51.07M8.88.48M+5.14%+$2.5M<0.01
The Vanguard Group$29.57M5.14.91M+11.99%+$3.17M<0.01
Ecor1 Capital Llc$24.42M4.214.06M0%+$00.17
State Street$23.57M4.063.92M+25.59%+$4.8M<0.01
Deep Track Capital Lp$22.69M3.913.77MNew+$22.69M0.1
Morgan Stanley$19.9M3.433.3M-28.93%-$8.1M<0.01
Deutsche Bank$15.91M2.742.64M+28.16%+$3.5M0.01
Braidwell Lp$14.33M2.472.38M-28.39%-$5.68M0.81
JPMorgan Chase$10.33M1.781.72M-7.95%-$892,368.66<0.01
Geode Capital Management$9.49M1.641.58M+14.04%+$1.17M<0.01
Euclidean Capital Llc$7.87M1.361.31M0%+$01.01
Verition Fund Management Llc$7.54M1.31.25M+755.63%+$6.66M0.07
Deerfield Management$6.46M1.111.07M+0.47%+$30,310.700.02
Franklin Templeton Investments$5.78M1959,5240%+$0<0.01
Jacobs Levy Equity Management$5.56M0.96922,799+16.18%+$773,660.300.02
DAFNA Capital Management, LLC$5.5M0.95912,928+49.68%+$1.82M0.13
T. Rowe Price$5.36M0.92890,494-25.89%-$1.87M<0.01
Dimensional Fund Advisors$5.09M0.88845,964+10.67%+$491,051.37<0.01
AllianceBernstein$4.37M0.75725,686+47.41%+$1.41M<0.01
Point72 Asset Management$4.19M0.72695,300+400.22%+$3.35M0.01
Renaissance Technologies$4.07M0.7675,483+18.09%+$623,007.540.01
Charles Schwab$4.06M0.7674,790+35.09%+$1.06M<0.01
Northern Trust$4.03M0.7670,223+9.06%+$335,115.30<0.01
Sphera Fund$3.37M0.58560,000New+$3.37M0.02
Two Sigma Advisers LP$3.25M0.56539,500+37.24%+$881,328.000.01
Eversept Partners LP$3.23M0.56536,171New+$3.23M0.25
Acadian Asset Management$2.67M0.46444,647+211.57%+$1.82M0.01
Two Sigma$2.2M0.38364,629+89.37%+$1.04M<0.01
Bank of America$2.13M0.37353,651-19.68%-$521,717.28<0.0001
Nuveen$2.05M0.35339,884-21.45%-$558,698.23<0.01
New Leaf Venture Partners$2.04M0.35339,5690%+$01.95
D. E. Shaw & Co.$1.98M0.34329,625+79%+$875,777.34<0.01
Baillie Gifford Co$1.94M0.34322,829-6.68%-$139,031.93<0.01
Goldman Sachs$1.92M0.33319,265+11.67%+$200,899.51<0.0001
Rafferty Asset Management Llc$1.66M0.29275,630+44.38%+$510,008.500.01
Alyeska Investment Group L P$1.54M0.27256,182New+$1.54M0.01
Walleye Capital$1.52M0.26252,808-3.56%-$56,094.35<0.01
Citigroup$1.45M0.25240,976+191.94%+$953,760.30<0.01
Jupiter Fund Management$1.4M0.24232,2190%+$0<0.01
BNY Mellon$1.39M0.24230,313+10.17%+$127,991.20<0.0001
UBS$1.38M0.24229,486+28.43%+$305,779.94<0.0001
Panagora$1.32M0.23219,704-7.16%-$101,984.810.01
AQR Capital$1.15M0.2190,210+189.66%+$749,748.73<0.01
Woodline Partners LP$1.14M0.2190,000New+$1.14M0.01
Nordea Investment Management Ab$1.16M0.2188,767-0.8%-$9,351.22<0.01
Medici Capital Llc$1.12M0.19185,929-3.54%-$41,044.381.28
Marshall Wace$1.07M0.18177,278New+$1.07M<0.01
Alphabet$1.06M0.18175,8660%+$00.01
Stifel$883,068.000.15146,688+0.64%+$5,592.62<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.